Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTNMNASDAQ:HILSNASDAQ:RAPTNASDAQ:SGMT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTNMContineum Therapeutics$3.51-10.9%$5.29$3.49▼$22.00$90.81MN/A80,274 shs126,687 shsHILSHillstream BioPharma$1.33+0.4%$1.35$0.19▼$2.65$23.41M3.081.39 million shs25,553 shsRAPTRAPT Therapeutics$0.84+3.7%$1.00$0.71▼$4.83$110.92M-0.041.27 million shs592,690 shsSGMTSagimet Biosciences$3.22-2.7%$3.06$1.73▼$7.38$98.77M2.32862,032 shs350,568 shsFree Today: Your Guide to Smarter Options TradesLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTNMContineum Therapeutics0.00%-9.30%-24.03%-54.59%-77.07%HILSHillstream BioPharma+0.38%-11.92%+15.65%-30.00%+264.78%RAPTRAPT Therapeutics0.00%+8.90%+6.07%-30.13%-80.25%SGMTSagimet Biosciences0.00%-0.62%+45.70%-24.24%-30.30%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCTNMContineum Therapeutics2.5897 of 5 stars3.64.00.00.01.00.00.6HILSHillstream BioPharmaN/AN/AN/AN/AN/AN/AN/AN/ARAPTRAPT Therapeutics4.3186 of 5 stars3.13.00.04.23.61.71.3SGMTSagimet Biosciences2.47 of 5 stars3.42.00.00.02.62.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTNMContineum Therapeutics 3.20Buy$23.75576.64% UpsideHILSHillstream BioPharma 0.00N/AN/AN/ARAPTRAPT Therapeutics 2.17Hold$4.00377.04% UpsideSGMTSagimet Biosciences 2.80Moderate Buy$22.40595.65% UpsideCurrent Analyst Ratings BreakdownLatest HILS, RAPT, CTNM, and SGMT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025CTNMContineum TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$31.00 ➝ $31.003/13/2025CTNMContineum TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$23.003/11/2025SGMTSagimet BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.003/10/2025RAPTRAPT TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/7/2025CTNMContineum TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$25.00 ➝ $25.003/7/2025CTNMContineum TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$32.00 ➝ $16.00(Data available from 5/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTNMContineum Therapeutics$50M1.82$0.55 per share6.35($3.72) per share-0.94HILSHillstream BioPharmaN/AN/AN/AN/A$0.48 per shareN/ARAPTRAPT Therapeutics$1.53M72.50N/AN/A$4.27 per share0.20SGMTSagimet Biosciences$2M49.39N/AN/A$3.98 per share0.81Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTNMContineum Therapeutics$22.72M-$1.97N/AN/AN/AN/A-49.92%-20.52%N/AHILSHillstream BioPharma-$8.47M-$0.72N/AN/AN/AN/A-188.44%-149.61%N/ARAPTRAPT Therapeutics-$116.80M-$2.40N/AN/AN/AN/A-89.10%-76.13%N/ASGMTSagimet Biosciences-$27.88M-$1.76N/AN/AN/AN/A-23.63%-22.91%5/21/2025 (Estimated)Latest HILS, RAPT, CTNM, and SGMT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025Q1 2025SGMTSagimet Biosciences-$0.79N/AN/AN/AN/AN/A5/14/2025Q1 2025CTNMContineum Therapeutics-$0.56-$0.62-$0.06-$0.62$7.50 millionN/A5/8/2025Q1 2025RAPTRAPT Therapeutics-$0.31-$0.08+$0.23-$0.08N/AN/A5/8/2025Q1 2025SGMTSagimet Biosciences-$0.79-$0.56+$0.23-$0.56N/AN/A3/12/2025Q4 2024SGMTSagimet Biosciences-$0.65-$0.50+$0.15-$0.50N/AN/A3/6/2025Q4 2024RAPTRAPT Therapeutics-$0.45-$1.14-$0.69-$1.14N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCTNMContineum TherapeuticsN/AN/AN/AN/AN/AHILSHillstream BioPharmaN/AN/AN/AN/AN/ARAPTRAPT TherapeuticsN/AN/AN/AN/AN/ASGMTSagimet BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTNMContineum TherapeuticsN/A37.0637.06HILSHillstream BioPharmaN/A3.013.01RAPTRAPT TherapeuticsN/A9.909.90SGMTSagimet BiosciencesN/A38.4138.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTNMContineum TherapeuticsN/AHILSHillstream BioPharma13.36%RAPTRAPT Therapeutics99.09%SGMTSagimet Biosciences87.86%Insider OwnershipCompanyInsider OwnershipCTNMContineum Therapeutics11.30%HILSHillstream BioPharma30.24%RAPTRAPT Therapeutics6.60%SGMTSagimet Biosciences14.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTNMContineum Therapeutics3125.87 millionN/AN/AHILSHillstream BioPharma117.60 million12.28 millionNot OptionableRAPTRAPT Therapeutics80132.29 million32.65 millionOptionableSGMTSagimet Biosciences830.68 million25.28 millionOptionableHILS, RAPT, CTNM, and SGMT HeadlinesRecent News About These CompaniesSagimet Biosciences (SGMT) Expected to Announce Earnings on WednesdayMay 16 at 2:20 AM | marketbeat.comSagimet Biosciences Inc. (NASDAQ:SGMT) Shares Purchased by Bridgeway Capital Management LLCMay 13, 2025 | marketbeat.comSagimet Biosciences (SGMT) & Its Rivals Critical AnalysisMay 11, 2025 | americanbankingnews.comRenaissance Technologies LLC Sells 220,300 Shares of Sagimet Biosciences Inc. (NASDAQ:SGMT)May 10, 2025 | marketbeat.comSagimet Biosciences Inc.: Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate UpdatesMay 9, 2025 | finanznachrichten.deSagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate UpdatesMay 8, 2025 | globenewswire.comSagimet Biosciences Inc. (NASDAQ:SGMT) Shares Sold by Alyeska Investment Group L.P.May 8, 2025 | marketbeat.comBoothbay Fund Management LLC Has $56,000 Stock Holdings in Sagimet Biosciences Inc. (NASDAQ:SGMT)May 7, 2025 | marketbeat.comSagimet Biosciences Inc. (NASDAQ:SGMT) Shares Sold by Baker BROS. Advisors LPMay 6, 2025 | marketbeat.com138,263 Shares in Sagimet Biosciences Inc. (NASDAQ:SGMT) Bought by 683 Capital Management LLCMay 4, 2025 | marketbeat.comBlue Owl Capital Holdings LP Has $5.96 Million Stake in Sagimet Biosciences Inc. (NASDAQ:SGMT)April 26, 2025 | marketbeat.comSagimet Biosciences announces presentations at EASL Congress 2025April 25, 2025 | markets.businessinsider.comSagimet Biosciences to Present Phase 2b FASCINATE-2 Study Findings on Denifanstat at EASL Congress 2025April 23, 2025 | quiverquant.comWhy Sagimet Biosciences Inc.’s (SGMT) Stock Is Up 7.11%April 23, 2025 | aaii.comSagimet Biosciences Announces Upcoming Presentations at EASL Congress 2025April 23, 2025 | finance.yahoo.comWhy Sagimet Biosciences Inc.’s (SGMT) Stock Is Down 14.92%April 7, 2025 | aaii.comWhy Sagimet Biosciences Inc.’s (SGMT) Stock Is Down 12.37%March 31, 2025 | aaii.comSagimet Biosciences Gets Clearance To Initiate Phase 1 Study Of TVB-3567 For Treatment Of AcneMarch 13, 2025 | nasdaq.comSagimet Biosciences Inc.: Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of AcneMarch 12, 2025 | finanznachrichten.deSagimet Biosciences reports Q4 EPS (50c), consensus (63c)March 12, 2025 | markets.businessinsider.comSagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate UpdatesMarch 12, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHILS, RAPT, CTNM, and SGMT Company DescriptionsContineum Therapeutics NASDAQ:CTNM$3.51 -0.43 (-10.91%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$3.62 +0.12 (+3.28%) As of 05/16/2025 06:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.Hillstream BioPharma NASDAQ:HILS$1.33 +0.01 (+0.38%) As of 05/16/2025Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) and targeted immuno-oncology novel biologics for the treatment drug resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-3215, an anti-HER2 monoclonal antibody candidate; and HSB-1940, a Quatrabody that is a proprietary IO biologic in development targeting PD-1. The company was incorporated in 2017 and is based in Bridgewater, New Jersey.RAPT Therapeutics NASDAQ:RAPT$0.84 +0.03 (+3.66%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$0.86 +0.03 (+3.04%) As of 05/16/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb CompanySagimet Biosciences NASDAQ:SGMT$3.22 -0.09 (-2.72%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$3.20 -0.02 (-0.47%) As of 05/16/2025 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/12 - 05/16 Retail Investors Are Betting Big on Rocket Lab—Should You Too? Meta's 5 Key Pillars for AI Growth—Zuckerberg's Bold Vision Taiwan Semiconductor Stock Is The Gift That Keeps on Giving GE Aerospace: Qatar Deal Fuels Multi-Billion Dollar Growth Engine Alibaba's Earnings Just Changed Everything for the Stock Plug Power: Is Q1 Noise An Opportunity for Accumulation? Cisco Stock Eyes New Highs in 2025 on AI, Earnings, Upgrades Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
